# Receptor Specific Retinoids Probes to Study the Brain Damage Caused byDevelopmental Alcohol Exposure

> **NIH NIH R21** · LONG ISLAND UNIVERSITY BROOKLYN CAMPUS · 2020 · $194,293

## Abstract

ABSTRACT
Alcohol intake during pregnancy causes wide varieties of acute and long-lasting adverse effects on fetuses,
resulting in fetal alcohol spectrum disorders (FASD) in offspring. Especially, the developing brain is sensitive to
alcohol toxicity, and impairments in cognitive functions, such as learning and memory, can be seen in FASD
patients. While many factors may be involved in alcohol toxicity in the developing brain, the retinoic acid (RA)
signaling pathway is often implicated in the process of alcohol toxicity, because RA (the active form of vitamin
A) that regulates transcription and translation via nuclear RA receptors plays an important role in the
development of embryos and their CNS, and alcohol has been shown to disturb retinoid (compounds related to
vitamin A) metabolism. While precise control of RA distribution within embryonic cell populations seems to be
necessary, and the excess or depletion of RA in the CNS has been shown to disturb brain development, alcohol
interferes with retinoid metabolism by several mechanisms, resulting in activation or inactivation of the RA
signaling pathway. Therefore, the RA signaling pathway may serve as a target for developing therapeutic
applications in alcohol toxicity in the developing brain. This translational research proposal aims to determine if
administration of novel retinoid derivatives (RA receptor agonists and antagonists) synthesized in the laboratory
of Dr. Bhaskar Das (PI, Icahn School of Medicine at Mount Sinai) alleviates prenatal or neonatal alcohol-induced
acute neurodegeneration as well as long-lasting abnormalities in neurogenesis, neuroanatomy, and behavior,
using mouse models of FASD in the laboratory of Dr. Mariko Saito (Co-PI, Nathan Kline Research Institute). The
specific aims of this project are: Aim. 1: To synthesize additional novel retinoids from our lead molecules that
are fully characterized for specificity and bioactivity (Dr. Das’ s group; see Nature Chemical Biology 2013 PMID:
23584676, PLos One 2011 PMID:22125642 and PLos One 2010 PMID: 20368991). Then we will iterate the
process to synthesize additional compounds, which are more resistant to protease cleavage, more potent, and
more specific to receptors. In the specific Aim 2, we will determine if RA receptor agonists or antagonists prevent
early alcohol-induced abnormalities in cell survival, neurogenesis, neuroanatomy and behaviors. Alcohol, with
or without RA derivatives, will be injected into dams at gestational day 8 (GD8) (1st trimester model) or pups at
postnatal day 7 (P7) (3rd trimester model), and we will assess whether RA derivatives attenuate alcohol-induced
acute neurodegeneration and long-lasting abnormalities in neurogenesis, GABAergic cell densities, and
behaviors (locomotor activity and contextual fear conditioning). Successful completion of this translational
research program will help identify target retinoid derivatives to be developed for the treatment for FASD.

## Key facts

- **NIH application ID:** 10203693
- **Project number:** 7R21AA027374-02
- **Recipient organization:** LONG ISLAND UNIVERSITY BROOKLYN CAMPUS
- **Principal Investigator:** Bhaskar Chandra Das
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $194,293
- **Award type:** 7
- **Project period:** 2019-09-10 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10203693

## Citation

> US National Institutes of Health, RePORTER application 10203693, Receptor Specific Retinoids Probes to Study the Brain Damage Caused byDevelopmental Alcohol Exposure (7R21AA027374-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10203693. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*